For how we live.
4CMenB had shown promise against gonorrhoea in observational data. Randomised, its efficacy was minus 0.5%. In the same field, a once-weekly oral HIV regimen met non-inferiority at 48 weeks.
Nine countries have launched lenacapavir for HIV prevention, with roughly 66,000 people newly started on it. In at least two countries, demand has already outrun the available doses.
The recommendation covers people weighing at least 35 kg and rests on two trials in which lenacapavir cut HIV infections by 100% and 96% against background incidence.
The guidelines pair the new injectable with a second, quieter recommendation: use simplified rapid diagnostic testing to start and continue long-acting PrEP, rather than more complex assays.
Lenacapavir is the first HIV pre-exposure prophylaxis given every six months. Two phase 3 trials found zero and two infections in the lenacapavir groups against background rates above 2 per 100 person-years.